The mission of the HESI Microbiome Subcommittee is to examine gut microbial-host dynamics to understand how the gut microbiome affects human health, drug efficacy and xenobiotic toxicity. The focus is to identify markers contributing to or resulting from disease or organ damage, including:
- alterations of the microbial community structure and microbiome function;
- endogenous microbial metabolites;
- and/or microbiota metabolism of exogenous compounds.
View the proposal presented at the 2016 Annual Meeting here.
Donna Mendrick, PhD
US Food and Drug Administration / National Center for Toxicology Research
Vicki Sutherland, PhD
National Institute of Environmental Health Sciences / National Toxicology Program
Members and Fact Sheet
There is an increasing awareness that the gut microbiome plays a critical role in human health and disease, but mechanistic insights are often lacking. In June 2018, HESI held a workshop, “The Gut Microbiome: Markers of Human Health, Drug Efficacy and Xenobiotic Toxicity” to identify data gaps in determining how gut microbiome alterations may affect human health. A series of key recommendations were formulated to focus efforts to further understand host-microbiome interactions and the consequences of exposure to xenobiotics as well as identifying biomarkers of microbiome-associated disease and toxicity.